•  
  •  
  •  
  •  

2023-01-29 21:21:36

  • Home
  • Commodities
  • Industry News
  • IPO
  • Mutual Funds
  • Others
  • Research
  • Watch List
Latest News
  • HFCL Ltd and HTL Ltd receive orders worth Rs. 206.67 crores
  • Krsnaa Diagnostics operationalizes 1 Diagnostic Center in UP
  • Indiabulls Enterprises Ltd consolidated Q3FY23 profit at Rs. 1.51 crore
  • Capri Global Capital Ltd Q3 FY2023 consolidated net profit slides to Rs. 37.41 crores
  • CARE Ratings Ltd reports consolidated PAT of Rs. 15.95 crores in Q3FY23

Keywords Selected:  ZydusLifesciences

Stock Report

  • Zydus Lifesciences Ltd successfully completes USFDA inspection at Moraiya facility
  • Zydus receives tentative approval from the USFDA for Levomilnacipran Extended-Release Capsules
  • Zydus receives final approval and 180 days shared exclusivity from the USFDA for Brexpiprazole Tablets
  • Zydus receives final approval from the USFDA for Febuxostat Tablets
  • Zydus launches Topiramate Extended-Release Capsules
  • Zydus receives final approval from the USFDA for Triazolam Tablets
  • Zydus receives final approval and 180 days shared exclusivity from the USFDA for Selexipag Tablets
  • Zydus receives two final approvals from the USFDA for Silodosin capsules and Pregabalin capsules
  • Zydus receives final approval from the USFDA for Estradiol Transdermal System which will be manufactured at the Moraiya plant
  • Zydus receives final approval from the USFDA for Topiramate Extended-Release Capsules
  • Zydus Lifesciences Ltd enters into BTA for purchase from Watson Pharma Pvt Ltd
  • Zydus receives tentative approval from the USFDA for Levothyroxine Sodium for Injection
  • Zydus receives final approval from the USFDA for Famotidine Injection
  • Zydus Lifesciences gets exclusive marketing rights for CanAssist Breast
  • Zydus receives final approval from the USFDA for Bisoprolol Fumarate and Hydrochlorothiazide Tablets
  • Zydus receives EIR with VAI from USFDA for its Moraiya formulations manufacturing facility
  • Zydus receives final approval from the USFDA for Acetaminophen injection
  • Zydus receives final approval from the USFDA for Micafungin for Injection
  • Zydus receives tentative approval from the USFDA for Roflumilast Tablets
  • Zydus receives tentative approval from the USFDA for Valbenazine Capsules
  • Zydus receives final approval from USFDA and 180 days shared exclusivity for Brivaracetam Tablets
  • Zydus receives tentative approval from the USFDA for Amantadine Extended-Release Capsules
  • Zydus receives final approval from USFDA and 180 days shared exclusivity for Mirabegron Extended-Release Tablets
  • Zydus receives final approval from the USFDA for Sildenafil for Oral Suspension

Latest Post

  • HFCL Ltd and HTL Ltd receive orders worth Rs. 206.67 crores
  • Krsnaa Diagnostics operationalizes 1 Diagnostic Center in UP
  • Indiabulls Enterprises Ltd consolidated Q3FY23 profit at Rs. 1.51 crore
  • Capri Global Capital Ltd Q3 FY2023 consolidated net profit slides to Rs. 37.41 crores
  • CARE Ratings Ltd reports consolidated PAT of Rs. 15.95 crores in Q3FY23


Announcement

To Advertise in our website please e-mail us at advertisement@equitybulls.com
Companies can send their Press Releases to pressrelease@equitybulls.com

Links

  • Home
  • Contact
  • Our Team

Contact

The website is developed and maintained by Chennai Scripts
No:AP-172, 2nd Sector, 10th Street, KK Nagar
Chennai
Tamil Nadu
India
600078
E-mail: chennaiscripts@gmail.com
Mobile Phone Number: +91-80560-88967
www.chennaiscripts.com

Website Created & Maintained by : Chennai Scripts
West Mambalam, Chennai - 600 033,
Tamil Nadu, India

Disclaimer Copyright © - 2022